Comparative Pharmacology
Head-to-head clinical analysis: DILACOR XR versus KATERZIA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DILACOR XR versus KATERZIA.
DILACOR XR vs KATERZIA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Diltiazem inhibits calcium ion influx across cardiac and vascular smooth muscle cells, resulting in dilation of coronary and systemic arteries, decreased myocardial contractility, and reduced sinoatrial and atrioventricular conduction velocity.
KATERZIA (bosentan) is an endothelin receptor antagonist (ERA) that blocks endothelin-1 (ET-1) from binding to ETA and ETB receptors in the endothelium and vascular smooth muscle. This inhibits ET-1-mediated vasoconstriction and smooth muscle proliferation, reducing pulmonary vascular resistance and pulmonary arterial pressure.
180 to 240 mg orally once daily, administered on an empty stomach; maximum dose 480 mg once daily.
5 mg orally once daily for 21 days, then 7 days off, repeated in 28-day cycles.
None Documented
None Documented
Terminal half-life: 6-12 hours (prolonged in elderly, hepatic impairment, or with CYP3A4 inhibitors)
Terminal elimination half-life is approximately 9-12 hours in healthy adults. In patients with hypertension or hepatic impairment, half-life may be prolonged up to 15-20 hours, necessitating dose adjustment.
Renal (70% as metabolites, 3-4% as unchanged drug); biliary/fecal (25-30%)
Renal elimination accounts for approximately 60-80% of the administered dose, predominantly as unchanged drug via glomerular filtration and active tubular secretion. Biliary/fecal excretion is minimal, <5%.
Category C
Category C
Calcium Channel Blocker
Calcium Channel Blocker